Schnell to conduct Phase I trial for biosimilar drug
Schnell plans to develop and commercialize the drug candidate named GS 071 together with Japan’s Nichi-Iko Pharmaceuticals...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.